These results further confirmed the existence of IGF2-IGF1R-BACH1-IGF1R positive feedback loop in wild-type HCC cells, and linsitinib could disrupt this loop to reduce BACH1, IGF1R and PTK2 expression, as well as the phosphorylation of IGF1R and PTK2. The gene discussed is IGF2; the disease is hepatocellular carcinoma.